News

Major Discovery May Alter Thinking on Alzheimer’s Disease

Investigators at the Blancette Rockefeller Neurosciences Institute (BRNI) recently discovered that the most significant genetic risk factor associated with Alzheimer’s disease, the Apolipoprotein E4 (ApoE4) gene, leads to a decrease in brain synapses, which occurs frequently prior to the onset of amyloid plaques or tangles developing in Alzheimer’s patients. This discovery may alter the…

Aphios Granted Patent For Treatment Of Alzheimer’s Disease

Aphios Corporation recently announced that United States Patent 9,034,347 has been granted to the company’s lead compound to treat neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Hutchinson Disease and Down’s syndrome. Alzheimer’s disease, Parkinson’s disease, Hutchinson’s Disease, Kuru Creutzfeldt-Jakob disease, further spongiform encephalopathies and all neurodegenerative diseases in general remain enormous health problems with numerous…

Alzheimer’s Association Launches New Open-Access Journal

The existence of specific and reliable biomarkers for Alzheimer’s disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer’s disease progression…

White Matter Differences Identified in Early-stage Alzheimer’s Disease, Frontotemporal Dementia

Findings from a study recently conducted by neuropsychologist Christiane Möller as part of her doctoral work showed that patients with Alzheimer’s disease as well as behavioral variant frontotemporal dementia have large differences in their brains’ white matter. For her research, which is funded by the NWO’s National Initiative Brain & Cognition,…